Author

E. Yilmaz

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Bioengineering· 1 Microbiology· 1 Physiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 6 Approach:experimental assay· 5 Research Focus:drug response / drug discovery· 4 Research Focus:cell type annotation· 2 Approach:statistical model· 2 Approach:wet-lab / biochemical assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1

Frequent Co-Authors

A. Cingoz· 2 shared A. P. Cribbs· 2 shared T. Bagci-Onder· 2 shared U. Oppermann· 2 shared A. Al-Hakeem· 1 shared A. C. Aksu· 1 shared A. Ceylan· 1 shared A. D. Cavga· 1 shared

Activity by Year

2020-2024 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 18 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Cingoz

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Chromatin-focused genetic and chemical screens identify BRPF1 as a targetable vulnerability in Taxol-resistant triple-negative breast cancer

O. Yedier-Bayram, A. Cingoz, E. Yilmaz, A. C. Aksu, B. Esin, N. Pinarbasi Degirmenci, A. D. Cavga, B. Dedeoglu, B. Cevatemre, H. Syed, M. Philpott, A. P. Cribbs, U. Oppermann, N. Lack, C. ACILAN AYHAN, , T. Bagci-Onder

The paper identifies BRPF1 as a key regulator of Taxol resistance in TNBC through genetic and chemical screens, showing its inhibition sensitizes resistant cells to chemotherapy.

bioRxiv · Apr 16, 2024Cancer Biology

FABP4 as a Therapeutic Host Target Controlling SARS-CoV2 Infection

H. Baazim, E. Koyuncu, G. Tuncman, M. F. Burak, L. Merkel, N. Bahour, E. S. Karabulut, G. Y. Lee, A. Hanifehnezhad, Z. F. Karagoz, K. Foldes, I. Engin, A. G. Erman, S. Oztop, N. Filazi, , G. S. Hotamisligil

This study identifies FABP4 as a host target that modulates SARS-CoV-2 infection, showing that its inhibition reduces viral replication and lung damage in infected hamsters.

bioRxiv · Feb 10, 2024 · PreprintMicrobiology

Reliability metrics of outcome measures during the single and double leg drop jump tests

H. Celik, A. Yildirim, E. Unver, C. Mavili, E. Yilmaz, F. Ozturk, P. Arpinar-Avsar, S. A. Cinemre

This study assesses the reliability of outcome measures in single and double leg drop jump tests for collegiate athletes, finding high reliability for key metrics in both tests.

bioRxiv · Jul 10, 2022 · PreprintPhysiology

HologLev: Hybrid Magnetic Levitation Platform Integrated with Lensless Holographic Microscopy for Density-Based Cell Analysis

K. Delikoyun, S. Yaman, E. Yilmaz, O. Sarigil, M. Anil Inevi, E. Ozcivici, H. C. Tekin

HologLev combines magnetic levitation with lensless holography for automated, low-cost cell density analysis, enabling cell separation and viability testing.

bioRxiv · Dec 10, 2020Bioengineering

Orthogonal targeting of KDM6A/B and HDACs mediates potent therapeutic effects in IDH1-mutant glioma

A. Kayabolen, E. Yilmaz, G. N. Sahin, F. Seker-Polat, A. Cingoz, B. Isik, S. Acar, S. Karahuseyinoglu, H. Wakimoto, D. P. Cahill, I. Solaroglu, A. P. Cribbs, U. Oppermann, T. Bagci-Onder

This study identifies GSK-J4 and Belinostat as effective therapies for IDH1-mutant glioma by targeting KDM6A/B and HDACs, showing synergistic effects in vitro and in vivo.

bioRxiv · Nov 26, 2020 · PreprintCancer Biology

Targeted CRISPR screening identifies PRMT5 as synthetic lethality combinatorial target with gemcitabine in pancreatic cancer cells

X. Wei, J. Yang, S. J. Adair, C. Kuscu, K. Y. Lee, W. Kane, P. E. O'Hara, D. Liu, Y. M. Demirlenk, A. H. Habieb, E. Yilmaz, A. Dutta, T. Bauer, M. Adli

The paper identifies PRMT5 as a synthetic lethal target with gemcitabine in pancreatic cancer using CRISPR screening in a PDX model.

bioRxiv · May 25, 2020Cancer Biology